Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK

BACKGROUND AND OBJECTIVE: The phase III ALFA-0701 study demonstrated the efficacy and safety of gemtuzumab ozogamicin (GO) versus standard of care (SOC) chemotherapy (daunorubicin and cytarabine) for the treatment of adult patients with de novo CD33+ acute myeloid leukaemia (AML). This study analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell-Smith, T. Alexander, Brockbank, James, Mamolo, Carla, Knight, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611158/
https://www.ncbi.nlm.nih.gov/pubmed/34181204
http://dx.doi.org/10.1007/s41669-021-00278-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611158/
https://www.ncbi.nlm.nih.gov/pubmed/34181204
http://dx.doi.org/10.1007/s41669-021-00278-3

Ejemplares similares